Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia

Medical Oncology

Volumn 28, Issue 2, 2011, Pages 532-538

  Kaufman, Matthew S ^a   Caramanica, Angelica ^a   Janson, Dale ^a   Driscoll, Nancy ^b   Johnson, Christina ^a   Kohn, Nina ^c   Wasil, Tarun ^a   Rai, Kanti R ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Alemtuzumab; B lymphocytes; Chronic lymphocytic leukemia; Immunotherapy; Maintenance therapy; T lymphocytes

Indexed keywords

ALEMTUZUMAB; MOXIFLOXACIN;

ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BACTERIAL PNEUMONIA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE FREE INTERVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS;

EID: 85027943274     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9478-3     Document Type: Article

References (7)

1. BD Cheson JM Bennett M Grever, et al. 1996 National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 87 4990 4997 8652811 1:CAS:528:DyaK28XjsFGisb8%3D (Pubitemid 26189840)
2. Cancer Therapy Evaluation Program 1 Revised March 23, 1998. Common Toxicity Criteria, Version 2.0 DCTD, NCI, NIH, DHHS March 1998.
3. MJ Keating S O'Brien D Kontoyiannis, et al. 2002 Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia Leuk Lymph 43 9 1755 1762 10.1080/1042819021000006547 1:CAS:528:DC%2BD38XntVKjsb4%3D (Pubitemid 34874007)
4. C Thieblemont F Bouafia E Hornez C Dumontet S Tartas D Antal, et al. 2004 Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) Leuk Lymph 45 711 714 10.1080/ 10428190310001615675 1:CAS:528:DC%2BD3sXpvV2ltr4%3D (Pubitemid 38256030)
5. M Montillo A Tedeschi, et al. 2006 Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia J Clin Oncol 24 2337 2342 16618945 10.1200/JCO.2005.04.6037 1:CAS:528:DC%2BD28XlvV2ksb0%3D (Pubitemid 46630666)
6. SM O'Brien HM Kantarjian DA Thomas, et al. 2003 Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia Cancer 98 2657 2663 14669286 10.1002/cncr.11871 (Pubitemid 37509530)
7. F Willis JC Marsh DH Bevan SB Killick G Lucas R Griffiths W Ouwehand G Hale H Waldmann EC Gordon-Smith 2001 The effect of treatment with Campath-1H in patients with autoimmune cytopenias Br J Haematol 114 4 891 898 11564082 10.1046/j.1365-2141.2001.03039.x 1:CAS:528:DC%2BD3MXnvVCgtL8%3D (Pubitemid 32953751)